Additionally, future studies should investigate how these targets interact with known MM drivers, and whether combining an ORM1/OVGP1-targeted approach with existing therapies (like proteasome inhibitors or immunotherapies) yields synergistic benefits. This evidence concerns the gene ORM1 and Miyoshi myopathy.